New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data

Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip

(2017) Michaela Luconi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro

(2016) Xian-wei Wang et al.   ACTA PHARMACOLOGICA SINICA

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

(2016) Rury R. Holman et al.   AMERICAN HEART JOURNAL

Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats

(2016) T.-M. Lee et al.   BIOSCIENCE REPORTS

Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications

(2016) Philippe Gabriel Steg et al.   CIRCULATION

Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

(2016) Kristy Iglay et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

(2016) Simon A. Hawley et al.   DIABETES

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway

(2016) Valentina Vellecco et al.   DIABETES OBESITY & METABOLISM

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

(2016) Naveed Sattar et al.   DIABETOLOGIA

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials

(2016) J. Kongwatcharapong et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis

(2016) Gianluigi Savarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease

(2016) Shingo Kato et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase

(2016) SONG-TAO TANG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase

(2016) Anna Solini et al.   VASCULAR PHARMACOLOGY

Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine

(2016) Jessica A. Hiemstra et al.   Journal of the American Heart Association

Sarcoplasmic reticulum Ca2+ ATPase pump is a major regulator of glucose transport in the healthy and diabetic heart

(2015) Amanda P. Waller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

(2015) Benjamin M. Scirica et al.   CIRCULATION

Dipeptidyl Peptidase-4 Inhibition Attenuates Arrhythmias via a Protein Kinase A-Dependent Pathway in Infarcted Hearts

(2015) Tsung-Ming Lee et al.   CIRCULATION JOURNAL

DPP4 in Cardiometabolic Disease: Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition

(2015) J. Zhong et al.   CIRCULATION RESEARCH

Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 AxisCLINICAL PERSPECTIVE

(2015) Morihiko Aoyama et al.   Circulation-Heart Failure

Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium

(2015) Markus Wallner et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats

(2015) Md. Ashraful Alam et al.   Diabetology & Metabolic Syndrome

Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α

(2015) Kim A. Connelly et al.   Journal of Diabetes

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

(2015) Wellington Santana da Silva Júnior et al.   Biomed Research International

Dipeptidyl-Peptidase-4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low-Density Lipoprotein (LDL) Receptor-Deficient Mice

(2015) K. Akita et al.   Journal of the American Heart Association

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

(2014) Mitchel Tate et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats

(2014) Toru Miyoshi et al.   Cardiovascular Diabetology

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4

(2014) N. Hamdani et al.   CARDIOVASCULAR RESEARCH

Vildagliptin Stimulates Endothelial Cell Network Formation and Ischemia-induced Revascularization via an Endothelial Nitric-oxide Synthase-dependent Mechanism

(2014) Masakazu Ishii et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat

(2014) Amy C. Keller et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors

(2014) Na-Hyung Kim et al.   Biomed Research International

Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats

(2013) Nattayaporn Apaijai et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials

(2013) Pitchai Balakumar et al.   CELLULAR SIGNALLING

Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model

(2013) P. Richards et al.   DIABETES

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia–reperfusion rat heart

(2013) Kroekkiat Chinda et al.   Diabetes & Vascular Disease Research

Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats

(2013) Annayya R. Aroor et al.   ENDOCRINOLOGY

The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes

(2013) T-I Lee et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

(2013) Paulus Wohlfart et al.   Journal of Translational Medicine

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

(2013) Minsuk Kim et al.   NATURE MEDICINE

DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes

(2012) Kim Alexander Connelly et al.   Cardiovascular Therapeutics

Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats

(2012) R. Preston Mason et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

(2011) Meimei Yin et al.   Cardiovascular Diabetology

G Protein–Dependent and G Protein–Independent Signaling Pathways and Their Impact on Cardiac Function

(2011) Douglas G. Tilley   CIRCULATION RESEARCH

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice

(2011) M. Angelyn Bethel et al.   Current Cardiology Reports

Troglitazone stimulates β-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor

(2010) Douglas G. Tilley et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

(2010) J. Koska et al.   DIABETES CARE

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Functional effects of glucose transporters in human ventricular myocardium

(2010) Dirk von Lewinski et al.   EUROPEAN JOURNAL OF HEART FAILURE

β-Arrestin–dependent activation of Ca2+/calmodulin kinase II after β1–adrenergic receptor stimulation

(2010) Supachoke Mangmool et al.   JOURNAL OF CELL BIOLOGY

Role of myocardial viscoelasticity in disturbances of electrical and mechanical activity in calcium overloaded cardiomyocytes: Mathematical modeling

(2010) Leonid B. Katsnelson et al.   JOURNAL OF THEORETICAL BIOLOGY

Glucose-transporter–mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients

(2010) Dirk von Lewinski et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

The cAMP binding protein Epac regulates cardiac myofilament function

(2009) O. Cazorla et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prevention of Heart Failure

(2008) Douglas D. Schocken et al.   CIRCULATION